Enterprise Value
45.23M
Cash
48.51M
Avg Qtr Burn
-25.21M
Short % of Float
7.20%
Insider Ownership
6.01%
Institutional Own.
33.78%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AFM24 (tumor target EGFR) w/ SNK01 & atezolizumab Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 2 Data readout | |
AFM13 (Acimtamig) + AB-101 Details Lymphoma, Cancer, Hodgkin Lymphoma, peripheral T-cell lymphomas | Phase 2 Data readout | |
AFM13 (Acimtamig)+ cbNK cells Details Cancer, Non-Hodgkin lymphoma | Phase 2 Update | |
AFM13 (Acimtamig) Details Peripheral T cell cancer , Cancer | Phase 2 Initiation | |
AFM28 Details Cancer, Leukemia, Blood cancer, Acute myeloid leukemia | Phase 1 Data readout | |
AFM24 (tumor target EGFR) Monotherapy Details Solid tumor/s, Cancer, Non-small cell lung carcinoma, Colorectal cancer | Failed Discontinued | |
RO7297089 (formerly AFM26) Details Multiple myeloma, Cancer | Failed Discontinued |